Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy

Inclusion Criteria Patients must have: HIV infection. Cutaneous, visceral, or ocular varicella-zoster viral infection. Refractory or intolerant to acyclovir or foscarnet therapy. Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Inability to take oral capsules or tolerate liquids. Concurrent Medication: Excluded: 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid. Patients with the following prior condition are excluded: History of immediate hypersensitivity to nucleoside analogues. Prior Medication: Excluded: 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry. Required: Prior acyclovir or foscarnet.